Imperial Brands (IMBLN; Baa3 Pos/BBB S/BBB S) 1H24 (6m ending March)
Aggressive pricing helping it hold onto organic growth (for now). Imperial, similar to BAT, is geographically diversified but that's where the positives stop - it has the lowest non-combustibles exposure (below) and this should leave it well wide of comps regardless of leverage goals. 33s look tad rich on this note, 31s look fair now (below). For those eyeing carry our preferred name in BBB tobacco remains BAT, bar those with a firm view to avoid Euro regulation/markets (rotate to Altria then). Again normal disclosure that Tobacco tends to underperform on spread sell-offs. Its already let a £600m line roll-off and YE leverage target will require gross debt to come down more. With only a $1b line still due this year (June), we don't expect € supply.
- On sales: headline revenue at £15.1b (-2.3%yoy) & net revenue at £3.6b (-0.7% gross, cc+2.8%). Organic growth from pricing (+8.6%) offsetting volume (-6.3%) which it says was on industry contracting.
- On Market share; gains in US (+5ps), Spain (+50bps) & Australia (+10bps) offsetting declines in Germany (-25bps) & UK (-40bps). Europe made up 40% of sales (18% in Germany, 7% in UK & 5% in Spain), US 33% & remainder 25% in Africa, Asia, Australasia & Central & Eastern Europe.
- On Next Generation products (i.e. non-combustibles); revenue rose +16.8% & it says makes up 7% of European revenues. It has entered the US market with "Zone" - its oral nicotine brand, NGP's current make up 1% there and 1% in other 25% (see above). It has bumped group exposure by 1ppt to 4%, still well shy of comps (below).
- On BS: cash conversion 97% over last 12m, adj. net debt at £10.1b leaving leverage at 2.5x (flat yoy) & is targeting 2x leverage by year-end. £1.1b buyback in place this year of which £605m completed, £ interim dividend given 4% bump its paid out £914m this half. Targets £6b in equity returns over 3yr period.
- On Guidance: Deliver LSD cc growth in tobacco & NGP net revenues & MSD growth in adj. operating profit. Expects 2% headwind from FX on revenue & 3-3.5% headwind to operating profit. Net of FX, guidance looks flat on sales (in-line with consensus) & LSD positive on operating profit (tad above consensus).